CORVax12 Vaccine for COVID-19

The FDA has accepted the IND for OncoSec’s CORVax12 (a novel DNA-encodable vaccine that combines OncoSec’s immuno-stimulant IL-12 expression platform, TAVO™ (tavokinogene telseplasmid), with NIH’s DNA-encodable stabilized trimeric SARS-CoV-2 spike glycoprotein) to treat COVID-19.

The acceptance of the IND paves the way for the start of the planned Phase 1 clinical trial.  Providence is the sponsor of the planned clinical trial and, as such, is both conducting and funding it.

OncoSec is partnering with the Providence Health & Services and the Providence Cancer Center to develop CORVax12. Providence is among the largest not-for-profit network of hospitals in the U.S.

Providence will conduct the Phase 1, open-label study to evaluate the safety and immunogenicity of a plasmid encoding the SARS-CoV-2 spike protein alone or in combination with IL-12 (CORVax12, SARS-CoV-2 S glycoprotein plasmid DNA in combination with IL-12 plasmid) in up to 36 healthy volunteers. CORVax12 will be given as a prime and booster dose four weeks apart. Study participants will be subdivided in parallel age cohorts of 18-55 years old versus > 55 years old.

According to MarketWatch, there are only seven vaccine candidates being tested in human participants in the U.S., as of October 2020.

About CORVax12 

CORVax12 is the only DNA vaccine that uses an immune stimulant to promote an immune response against the SARS-CoV-2 virus. The CORVax vaccine approach combines the co-administration of TAVO™ (plasmid IL-12) with a DNA-encodable version of the SARS-CoV-2 spike or “S” glycoprotein to enhance immunogenicity of the component developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center. CORVax12 is designed to drive a coordinated vaccine response, capable of drawing upon the innate and adaptive humoral and cellular arms. This multi-pronged innate, adaptive and cellular immune response has the potential to generate a robust anti-viral response.


Our lead product candidate is being evaluated in multiple cancer indications, including melanoma and TNBC.



Our plasmid DNA delivery platform is designed to boost the body’s immune system to target and attack cancer.



We are committed to sharing the results of our research and clinical development programs.